

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT4719995

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
YANPING ZHAO	10/18/2017
HONGJUN WANG	10/18/2017
GONG LI	10/18/2017
YUANYUAN JIANG	10/18/2017
XIANG LI	10/18/2017
LIYING ZHOU	10/18/2017
YANAN LIU	10/18/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BEIJING TIDE PHARMACEUTICAL CO., LTD.
<b>Street Address:</b>	NO.8 EAST RONGJING STREET
<b>Internal Address:</b>	BDA
<b>City:</b>	BEIJING
<b>State/Country:</b>	CHINA
<b>Postal Code:</b>	100176
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15719867
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(703)684-8075
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	7036848007
<b>Email:</b>	mark.koper@leclairryan.com
<b>Correspondent Name:</b>	LECLAIRRYAN, A PROFESSIONAL CORPORATION
<b>Address Line 1:</b>	2318 MILL ROAD
<b>Address Line 2:</b>	SUITE 1100
<b>Address Line 4:</b>	ALEXANDRIA, VIRGINIA 22314
<b>ATTORNEY DOCKET NUMBER:</b>	58498.1001
<b>NAME OF SUBMITTER:</b>	MARK I. KOPER
<b>SIGNATURE:</b>	/MARK I. KOPER/

PATENT

<b>DATE SIGNED:</b>	12/06/2017
---------------------	------------

**Total Attachments: 8**

- source=58498-1001-to be recorded Assignment#page1.tif
- source=58498-1001-to be recorded Assignment#page2.tif
- source=58498-1001-to be recorded Assignment#page3.tif
- source=58498-1001-to be recorded Assignment#page4.tif
- source=58498-1001-to be recorded Assignment#page5.tif
- source=58498-1001-to be recorded Assignment#page6.tif
- source=58498-1001-to be recorded Assignment#page7.tif
- source=58498-1001-to be recorded Assignment#page8.tif

## ASSIGNMENT

WHEREAS, WE, Yanping ZHAO; Hongjun WANG; Gong LI; Yuanyuan JIANG; Xiang LI, Liying ZHOU; and Yanan LIU have invented certain new and useful improvements in and to the subject matter of:

### **RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF**

described in United States Patent Application No. 15/719,867, filed September 29, 2017, which claims priority to PCT application No. PCT/CN2017/091085 filed on June 30, 2017;

AND, WHEREAS, BEIJING TIDE PHARMACEUTICAL CO., LTD., having a place of business located at No.8 East Rongjing Street, BDA, Beijing, China 100176, (hereinafter "Assignee"), is desirous of acquiring certain rights to the improvements and under the aforesaid applications;

NOW, THEREFORE, in exchange for good and valuable consideration, receipt of which is hereby acknowledged, we each do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, our entire right, title and interest in and throughout the United States of America (including its territories and dependencies) to said improvements, the aforesaid applications, any other applications, including provisional, non-provisional, divisional, renewal, substitute, continuation, continuation-in-part, reexamination and reissue applications, based in whole or in part on any of the aforesaid applications or in whole or in part on said improvements, based in whole or in part on any of the aforesaid applications or in whole or in part on said improvements, and in and to any and all letters patent, including extensions thereof, which have been or may be granted on any of the aforesaid applications or on said improvements or any parts thereof;


AND we each hereby authorize and request our agents, LeClairRyan, A Professional Corporation, whose address is 2318 Mill Road, Suite 1100, Alexandria, VA, 22314, to insert hereon any identification necessary or desirable for recordation of this document, including the filing date and application number of said applications when known;

AND we each hereby agree for ourselves and our heirs, executors and administrators to execute without further consideration any further documents and instruments which may be necessary, lawful and proper in the prosecution of the aforesaid applications or in the preparation or prosecution of any continuing, substitute, divisional, renewal, reexamination or reissue application or in any amendments, extensions, post-grant review, inter partes review or derivation proceedings, supplemental examination or interference proceedings, that may be necessary to secure to ASSIGNEE its interest and title in and to said improvements or any parts thereof, and in and to said several patents or any of them;


AND we each hereby covenant for ourselves and our legal representatives, and agree with said ASSIGNEE, its successors and assigns, that we have granted no right or license to make, use, sell or offer to sell said improvements, to anyone except said ASSIGNEE, that prior to the execution of this deed, our right, title and interest in said improvements had not been otherwise encumbered, and that we each have not and will not execute any instrument in conflict therewith;

AND we each do hereby authorize and request the Director of the United States Patent and Trademark Office to issue any and all letters patent which may be granted upon said applications, or upon said improvements or any parts thereof when granted, to said ASSIGNEE.

2017.10.18  
Date

  
\_\_\_\_\_  
Yanping ZHAO

2017.10.18  
Date

  
\_\_\_\_\_  
Hongjun WANG

2017.10.18  
Date

李功  
Gong Li

2017.10.18  
Date

姜媛媛  
Yuanyuan JIANG

2017.10.18  
Date

李想  
Xiang Li



Date 2017.10.18

周丽莹  
Liying ZHOU

2017.10.18  
Date

刘亚男  
Yanan LIU